Perinatal brain injury is the leading cause of neurological mortality and morbidity in
childhood ranging from motor and cognitive impairment to behavioural and neuropsychiatric …

Cell therapy, particularly mesenchymal stem/stromal (MSC) therapy, has been investigated
for a wide variety of disease indications, particularly those with inflammatory pathologies …

Background Human mesenchymal stromal cell (MSC)-derived extracellular vesicles (EV)
revealed neuroprotective potentials in various brain injury models, including neonatal …

Outcomes of neonatal encephalopathy (NE) have improved since the widespread
implementation of therapeutic hypothermia (TH) in high-resource settings. While TH for NE …

Hypoxic ischemic encephalopathy (HIE) in neonates causes increased mortality and long-
term morbidity in surviving babies. Hypothermia (HT) has improved outcomes, however …

In term and near-term neonates with neonatal encephalopathy, therapeutic hypothermia
protocols are well established. The current focus is on how to improve outcomes further and …

The clinical translation of stem cells and their extracellular vesicles (EVs)-based therapy for
central nervous system (CNS) diseases is booming. Nevertheless, the insufficient CNS …

Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of morbidity and mortality
in newborns in both high-and low-income countries. The important determinants of its …

Neonatal encephalopathy is a leading cause of morbidity and mortality worldwide. Although
therapeutic hypothermia (HT) is now standard practice in most neonatal intensive care units …

There is a need to develop therapies for neonatal encephalopathy (NE) in low‐and middle‐
income countries (LMICs) where the burden of disease is greatest and therapeutic …